CD8 + cytotoxic T lymphocytes (CTLs) serve as central effectors in cancer immunotherapy by directly eliminating tumor cells. However, current clinical therapies face significant limitations. These ...

Three days post viral infection CD8 T cells (red) re-arrest with antigen presenting cells (cyan), where they are supplied with IL-2 by CD4 T cells (yellow), which migrate in a stop and go pattern. The ...

Efficient T-cell engineering is crucial for the success of CAR T-cell therapy research, but it requires multiple labor-intensive steps, including T-cell isolation, activation, and transduction.

The ability of immune cells—particularly CD8 + T cells—to launch a rapid burst of proliferation inside tumors is key to the success of modern day cancer immunotherapies. However, the factors and ...

Killer immune cells destroy cancer cells and cells infected by virus. These CD8 + T cells are activated after detection of viral infection or growth of "non-self" tumor cells. However, in chronic ...

Scientists have discovered that T cell receptors activate through a hidden spring-like motion that had never been seen before. This breakthrough may help explain why immunotherapy works for some ...

Magnetic nanoparticles engineered T cells inside living mice and guided them into solid tumors, achieving over 90% tumor ...

Clonally expanded CD8+ T cells are key drivers of alopecia areata, mediating epithelial cell death and immune infiltration. JAK inhibitors are approved for AA treatment, but recurrence is common, ...

Contrary to public concerns, receiving frequent COVID-19 booster vaccinations will not weaken the immune system, providing reassurance to vulnerable groups facing new variants. Study: No evidence of ...